Search Results
Your search for ,led matches 5950 pages
Showing 3551 - 3600International Oncologist Nagi S. El Saghir, MD, FACP, Returned Home to Make a Difference in Lebanon and Worldwide
Internationally renowned expert on the early detection, prevention, and treatment of younger women with breast cancer, Nagi S. El Saghir, MD, FACP, FASCO, was born on January 5, 1953, in Bint Jbeil, a village in southern Lebanon. His parents moved to Beirut in 1948, at the height of the...
Pioneering Researcher and Oncologist Volker S. Diehl, MD, Helped Unlock the ‘Black Box’ of Hodgkin Lymphoma
Volker S. Diehl, MD, the internationally renowned hematologist and researcher, was born in Berlin, Germany, on February 28, 1938—arguably one of the most tumultuous periods in world history. Germany had just invaded Austria, signaling the dark intentions of the Third Reich. In 1943, the air raids...
AUA 2018: More Than 40% of Prostate Biopsies May Have Been Avoided With Use of Assay for Detection
A multicenter study that validated the clinical performance of IsoPSA—a new blood test that has proven to be more accurate in predicting overall risk of prostate cancer than standard prostate-specific antigen (PSA)—was presented at the 13th Annual Meeting of the American Urological...
FDA Identifies Efficacy Issue in Clinical Trials of Pembrolizumab or Atezolizumab as Monotherapy in Urothelial Cancer With Low Expression of PD-L1
On May 18, the U.S. Food and Drug Administration (FDA) alerted health-care professionals, oncology clinical investigators, and the public about decreased survival associated with the use of pembrolizumab (Keytruda) or atezolizumab (Tecentriq) as monotherapy in clinical trials to treat patients with ...
Antoni Ribas, MD, Recognized for Research in Cancer Immunology
Antoni Ribas, MD, Professor of Medicine and Director of the Tumor Immunology Program at the University of California Jonsson Comprehensive Cancer Center, has been awarded the sixth American Association of Cancer Research–Cancer Research Institute Lloyd J. Old Award in Cancer Immunology. The award...
Stand Up To Cancer Launches Research Team to Detect Precursor Conditions of Multiple Myeloma
Stand Up To Cancer (SU2C) announced a $10 million award to a Stand Up To Cancer Dream Team focused on revolutionizing the treatment of multiple myeloma through the early detection of precursor conditions. In the hope of developing therapies to prevent myeloma in high-risk populations, the project...
For James Allison, PhD, Perseverance and Hard Science Are Paramount in Cancer Research
For this installment in the Living a Full Life series of articles, guest editor Jame Abraham, MD, interviewed immunology pioneer James Allison, PhD, Chair of the Department of Immunology, the Vivian L. Smith Distinguished Chair in Immunology, Director of the Parker Institute for Cancer Research,...
PARP Inhibitor Shows Promise in Patients With BRCA-Mutated Pancreatic Cancer
A targeted therapy that has been effective in fighting ovarian cancer in women, including those with BRCA1 and BRCA2 mutations, may also help patients with aggressive pancreatic cancer who harbor these mutations and have few or no other treatment options. An international team of researchers was...
The American Society of Clinical Oncology at a Glance
The American Society of Clinical Oncology (ASCO) held its first scientific Annual Meeting on April 9, 1965, in the Bellevue Stratford Hotel in Philadelphia. More than 70 members and invited guests attended the inaugural event, which featured three presentations on leukemia and multiple myeloma. The ...
ASCO Honors Leaders in Cancer Care With 2018 Special Awards
ASCO AND ASCO’s Conquer Cancer Foundation recognized winners of ASCO’s 2018 Special Awards and Conquer Cancer’s Women Who Conquer Cancer Mentorship Awards during the 2018 ASCO Annual Meeting, June 1 to June 4, in Chicago. The recipients of these awards included researchers, patient advocates, and...
Nancy L. Bartlett, MD, Moved From Engineering to Medicine After a Stint in the ER
Nationally recognized oncologist Nancy L. Bartlett, MD, had an early love for mathematics and a swooning aversion to the sight of blood. “I was born and reared in Kansas City, Missouri and am a Midwesterner at heart. No one in the family was involved in medicine. My mom was an elementary school...
Monica M. Bertagnolli, MD, FASCO, a Cattle Rancher’s Daughter, Becomes ASCO President
ASCO President-Elect Monica M. Bertagnolli, MD, FASCO, was born and reared in Wyoming, where her family ran a cattle ranch in the foothills of the snow-topped peaks of the Wind River Range (or “Winds” for short), a place of breathtakingly uncluttered vistas where the chief feature is the air...
Brentuximab Vedotin in Previously Untreated Stage III or IV Classical Hodgkin Lymphoma
On March 20, 2018, brentuximab vedotin (Adcetris) was approved for the treatment of adult patients with previously untreated stage III or IV classical Hodgkin lymphoma in combination with chemotherapy.1,2 Supporting Efficacy Data Approval was based on the findings of the open-label phase III...
Both Patients and Clinicians Face Challenges in Recognizing and Reporting Immune-Related Adverse Events
The publication of ASCO’s toxicity management guidelines for immune checkpoint antibodies by Brahmer and colleagues,1 reviewed in this issue of The ASCO Post, has been long awaited, considering more than 15 distinct indications have been granted by the U.S. Food and Drug Administration (FDA). The ...
ASCO Clinical Practice Guideline on Managing Immune-Related Adverse Events: Next Big Step for Immune Checkpoint Inhibitors
The publication of the ASCO clinical practice guideline for the management of immune therapy–related adverse events—reviewed in this issue of The ASCO Post—represents an important next step in the incorporation of checkpoint blocking antibodies as standard cancer treatment modalities.1 The U.S....
Here’s How ASCO Is Joining With Other Organizations to Reduce Obesity and Cancer Rates
GUEST EDITOR Prevention in Oncology is guest edited by Jennifer A. Ligibel, MD, Chair of ASCO’s Energy Balance Working Group and a member of ASCO’s Cancer Survivorship and Cancer Prevention Committees. Dr. Ligibel is Director of the Leonard P. Zakim Center for Integrative Therapies at Dana-Farber...
Treating Pediatric Glioma With Bevacizumab and Standard Treatment
Children with nonbrainstem high-grade glioma could benefit from potentially life-extending treatment if genetic testing was used to personalize therapy as it is in many adults, new research published by Mackay et al in Cancer Cell reported. Scientists analyzed the DNA of children taking an...
Serving as ASCO President Is One of the Best Jobs in the World
The opportunity to serve as ASCO President is the greatest honor of my professional career. It has been a pleasure and a highly rewarding experience to interact with our members and members of ASCO’s Board, executive leadership, and professional staff during my tenure. The year has allowed me to...
ASCO’s Incoming President Sets Her Goals for the Next Year
With all the advances in oncology care over the past decade, the most important contribution to high-quality care remains the personal connection between oncologist and patient, said Monica M. Bertagnolli, MD, FACS, FASCO, ASCO President-Elect, who will take the reins as ASCO’s 55th President...
Rivaroxaban May Reduce Risk of Venous Thromboembolism in Patients With Cancer
Patients with cancer have an increased risk of developing blood clots, with roughly one in five experiencing venous thromboembolism (VTE)—either deep-vein thrombosis (DVT) or pulmonary embolism (PE). Although there are many causes and risk factors for VTE, patients with cancer are...
Racial/Ethnic Disparities in the Quality of End-of-Life Care Among Patients With Lung Cancer
Significant disparities in the quality of end-of-life lung cancer care were found among racial/ethnic minorities, with higher odds of experiencing potentially preventable medical encounters during end of life as compared with non-Hispanic whites. These findings were published by Karanth et al in...
Genetic Counseling and Testing for Patients With Medulloblastoma
Researchers have identified six genes that predispose carriers to develop medulloblastoma and have used the discovery to craft genetic counseling and screening guidelines. The study was published by Waszak et al in The Lancet Oncology. St. Jude Children’s Research Hospital,...
Intravesical Instillation of Gemcitabine Postsurgery May Aid in Preventing Bladder Cancer Recurrence
Flushing the bladder with a common chemotherapy drug immediately after surgery significantly reduces the chances of bladder cancer returning, according to a study by Messing et al published in JAMA and led by SWOG. First author Edward M. Messing, MD, is Professor of Urology and...
ASCO Hosts Inaugural State of Cancer Care in America Event to Examine Issues in Precision Medicine
Precision medicine is changing cancer care in profound ways. It is expected that the number of patients who benefit from precision medicine will continue to increase in the coming years, as treatments become more effective and research yields more insights on patient populations who are most likely ...
New Laws Reduce Costs of Oral Cancer Drugs, but Not for All
The rising cost of anticancer drugs not only adds fiscal pressure to our overburdened health-care system, but also increases the stress on patients with cancer and their families. High out-of-pocket spending may cause significant financial toxicity, even for patients with good health insurance...
Now More Than Ever, the Oncology Pharmacist Can Play a Variety of Roles on the Health-Care Team
Susannah E. Koontz, PharmD, BCOP, FHOPA, is a consultant for clinical pharmacy services, research, and education in the areas of pediatric hematology/oncology, stem cell transplantation, and cellular therapy. She has held positions at the Children’s Cancer Hospital at The University of Texas MD...
Obesity in Cancer Survivors: Identifying Teachable Moments
OBESITY IS associated with poor survival in patients with cancer, but when research is translated into survivorship care, obese and overweight patients can experience better outcomes, according to Karen Basen-Engquist, PhD, MPH, Professor of Behavioral Science and Director of the Center for Energy...
Follow-up Too Short in Ovarian Cancer, Too Long in Other Gynecologic Malignancies
A STANDARDIZED 5-year period of surveillance by a gynecologic oncologist was found to be inadequate for some gynecologic cancers and excessive for others, according to research presented by Robert Dood, MD, of The University of Texas MD Anderson Cancer Center, Houston, at the 2018 Society of...
Evolving Standards and Quality Metrics Ensure High-Quality Cancer Programs
Dr. Shulman is Deputy Director, Clinical Services, and Director of the Center for Global Cancer Medicine, Abramson Cancer Center; and Professor of Medicine, Hospital of the University of Pennsylvania, Philadelphia. IN 2008, WHEN ALLEN LICHTER, MD, FASCO, then Chief Executive Officer of ASCO,...
Targeting Chemotherapy With Genetic Testing in Advanced Triple-Negative Breast Cancer
Researchers have found that women with advanced triple-negative breast cancer with a BRCA mutation were twice as likely to benefit from carboplatin as docetaxel—the current standard of care for these patients. These findings were published by Tutt et al in Nature Medicine. The trial is set...
Risk of Gastrointestinal Cancers in Patients With Cystic Fibrosis
In a meta-analysis reported in The Lancet Oncology, Yamada et al found that patients with cystic fibrosis are at increased risk of gastrointestinal (GI) cancers vs the general population. Improved management of cystic fibrosis has led to increased life expectancy and increased incidence of...
HPV-Related Cancers Like Mine Are Avoidable, So Why Aren’t More Kids Being Vaccinated?
The latest news from the Centers for Disease Control and Prevention about vaccination rates in the United States for human papillomavirus (HPV) is disappointing. It shows that in 2016, just 43.4% of adolescents (49.5% of females and 37.5% of males) were up-to-date with the recommended 3-dose HPV...
Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma
Updated results of a phase I/II study of durvalumab (Imfinzi) in locally advanced or metastatic urothelial carcinoma were reported by Thomas Powles, MD, of Barts Cancer Institute, Queen Mary University of London, and colleagues in JAMA Oncology. Data from the ongoing study supported the recent...
Disparities Found in Lung Cancer Care, Survival in United States vs England
Despite steady declines in death rates in recent years, lung cancer remains the leading cause of cancer deaths in wealthy countries. In a study published by Andreano et al in the Journal of Thoracic Oncology, Yale researchers collaborated with investigators in Europe to examine lung cancer care and ...
Multiple Myeloma Research Foundation Awards $7M to Advance Immunotherapy Research
The Multiple Myeloma Research Foundation announced that, as part of its $15M Immunotherapy Initiative, it has awarded $7 million to fund three research programs led by myeloma researchers. The Immunotherapy Initiative, through the formation of highly collaborative, multidisciplinary Immune Networks ...
Nivolumab in Adjuvant Treatment of Melanoma
On December 20, 2017, nivolumab (Opdivo) was granted regular approval for adjuvant treatment of patients with melanoma with lymph node involvement or metastatic disease who have undergone complete resection.1,2 Nivolumab was previously approved for the treatment of patients with unresectable or...
Combined Immune Checkpoint and VEGF Inhibition as First-Line Therapy in Advanced Clear Cell Kidney Cancer
In a dose-finding, dose-expansion phase Ib trial (JAVELIN Renal 100) reported in The Lancet Oncology, Toni K. Choueiri, MD, of Dana-Farber Cancer Institute and Brigham and Women’s Hospital, and colleagues determined the maximum tolerated dose of the immune checkpoint inhibitor avelumab (Bavencio)...
Men With Nonmelanoma Skin Cancer History May Have Reduced Risk of Death From Melanoma
Skin cancer survivors know firsthand that the disease is most treatable when detected early, so they’re more likely to be vigilant about skin exams—and new research shows that such vigilance pays off. After studying more than 900 cases of melanoma reported through the Health...
MGUS and Multiple Myeloma in 9/11 Firefighters
A study by Landgren et al in JAMA Oncology has found that New York City firefighters exposed to the 9/11 World Trade Center (WTC) disaster site face an increased risk for developing monoclonal gammopathy of undetermined significance (MGUS), a myeloma precursor disease. The study was conducted...
ESTRO 37: Brachytherapy for Patients With Cervical Cancer Does Not Increase Risk of Ureteral Stricture
A rare but potentially serious complication following radiation treatment for cervical cancer is a narrowing of the tube that takes urine from the kidneys to the bladder (the ureter), which can lead to kidney damage and sometimes life-threatening infections. This is called ureteral stricture and,...
Norman Wolmark, MD, and Bernard Fisher, MD, Honored for Leadership of NSABP
NORMAN WOLMARK, MD, and Bernard Fisher, MD, received the Society of Surgical Oncology (SSO) Distinguished Service Award for their work leading the National Surgical Adjuvant Breast and Bowel Project (NSABP). Dr. Wolmark, who succeeded Dr. Fisher as Chair of the NSABP and is currently Group Chair...
Neuroendocrine Tumor Research Foundation Awards Six Research Grants
THE NEUROENDOCRINE Tumor Research Foundation (NETRF) has awarded six new research grants, totaling about $1.85 million, to leading academic institutions around the world. The grants fund clinical, translational, and basic research in the United States, Australia, Switzerland, and the United...
Phase II Study of Sunitinib Schedule in Metastatic Renal Cell Carcinoma
In a phase II study reported in the Journal of Clinical Oncology, Jonasch et al found evidence that a 2-weeks-on/1-week-off (2/1) schedule of sunitinib (Sutent) might be an option in frontline treatment of metastatic renal cell carcinoma. Study Details In the study, 59 patients with previously...
St. Jude Cloud, Largest Public Repository of Pediatric Cancer Genomics Data, Launches for Researchers Worldwide
On April 12, St. Jude Children’s Research Hospital launched the St. Jude Cloud, an online data-sharing and collaboration platform that provides researchers access to the world's largest public repository of pediatric cancer genomics data. Developed as a partnership among St. Jude,...
Crizotinib in East Asian Patients With ROS1-Positive Advanced NSCLC
In a phase II study reported in the Journal of Clinical Oncology, Wu et al found that crizotinib (Xalkori) was highly active in East Asian patients with ROS1-positive advanced non–small cell lung cancer (NSCLC). Study Details In the study, 127 patients from 37 sites in China, Japan,...
ASCO Honors Leaders in Cancer Care With 2018 Special Awards
ASCO and ASCO’s Conquer Cancer Foundation are proud to recognize the winners of ASCO’s Special Awards and Conquer Cancer’s Women Who Conquer Cancer Mentorship Awards. The recipients of these awards include researchers, patient advocates, and global oncology leaders who have worked to transform...
A Career Based on Service: Both Medical and Military
For this installment in the Living a Full Life series of articles, Edith Peterson Mitchell, MD, was interviewed by Guest Editor Jame Abraham, MD, FACP. Dr. Mitchell is Clinical Professor of Medicine and Medical Oncology in the Division of Medical Oncology at Thomas Jefferson University as well as ...
AACR 2018: KEYNOTE-189: Addition of Pembrolizumab to Chemotherapy in Metastatic NSCLC
As reported at the American Association for Cancer Research (AACR) Meeting (Abstract CT075) in the The New England Journal of Medicine by Gandhi et al, the first interim analysis of the phase III KEYNOTE-189 trial has shown significant improvement in overall and progression-free survival with the...
AACR 2018: CheckMate 227: Nivolumab/Ipilimumab vs Chemotherapy in NSCLC With High Tumor Mutational Burden Analysis
As reported at the 2018 American Association for Cancer Research (AACR) Meeting (Abstract CT077) and in The New England Journal of Medicine by Hellmann et al, an analysis from the phase III CheckMate 227 trial has shown that the combination of nivolumab (Opdivo) plus ipilimumab (Yervoy)...
Leslie Bernstein, PhD, Receives AACR–American Cancer Society Award for Research Excellence
Biostatistician and epidemiologist Leslie Bernstein, PhD, Professor in the Division of Biomarkers of Early Detection and Prevention, Department of Population Sciences, at City of Hope, has been selected to receive the American Association for Cancer Research’s (AACR) 27th Annual American Cancer...
